Guilherme Nader Marta, Advanced Clinical Fellow at Dana-Farber Cancer Institute, shared on X:
“Inavolisib triplet approval marks real progress for patients with PIK3CA-mut HR+ mBC
With progress come new questions – on patient selection, toxicity and integration into practice
In this article we break down the data and its implications.”
Title: Inavolisib-Based Triplet Therapy for PIK3CA-Mutated Hormone Receptor+/HER2- Breast Cancer: Clinical Implications and Practical Considerations
Authors: Guilherme Nader-Marta, Sara M. Tolaney, Erica L. Mayer
